Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
Telix Pharmaceuticals Limited announced robust Q1 2026 financial results with 24% year-over-year revenue growth to $230 million and confirmed FY 2026 guidance between $950 million and $970 million. The company highlighted progress in its therapeutic pipeline, including successful completion of key safety objectives for its TLX591-Tx prostate cancer…